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Abstract Focal adhesion kinase (FAK) is an important
mediator of signal transduction pathways initiated by integrins
in cell migration, survival and cell cycle regulation. The ability of
FAK to mediate integrin signaling in the regulation of cell cycle
progression depends on the phosphorylation of Tyr397, which
implies a functional significance for the formation of FAK
signaling complexes with Src, phosphatidylinositol-3-kinase
(PI3K) and Grb7. We have previously described a FAK mutant,
D395A, that selectively disrupts FAK binding to PI3K, but
allows FAK association with Src. Using this mutation in a
mislocalized FAK mutant background, we show here that
formation of a FAK/PI3K complex is not sufficient for cell
cycle progression but the formation of a FAK/Src complex
plays an essential role. We also show that mutation of D395
to A disrupted FAK association with Grb7. This suggests
that a FAK/Grb7 complex is not involved in the cell cycle
regulation either, which is supported by direct analysis of cells
expressing a dominant negative Grb7 construct. Finally, we
provide evidence that the Src-dependent association of FAK with
Grb2 and p130Cas are both required for the regulation of cell
cycle progression by FAK. Together, these studies identify
important FAK downstream signaling pathways in cell cycle
regulation. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Focal adhesion kinase (FAK) is a 125 kDa protein tyrosine
kinase that plays a major role in signal transduction mediated
by integrins [1,2]. Integrin signaling through FAK has been
shown to regulate cell migration [3^5], proliferation [4,6] and
cell survival [7]. The ability of FAK to regulate these cellular
processes depends upon its localization to focal contacts and
its ability to form protein complexes with other signaling mol-
ecules [6,8^11].
Y397 is the major phosphorylation site in FAK [12]. Upon
phosphorylation, Y397 serves as the binding site for the SH2
domains of other proteins such as Src [13,14], phosphatidyl-
inositol-3-kinase (PI3K) [15], PLCQ1 [16] and Grb7 [17]. It has
been shown previously that Asp395 in FAK is critical for the
association of PI3K with FAK at Y397, but mutation of this
residue to Ala has no e¡ect on FAK/Src association [9,11].
Use of this mutant allows the direct examination of FAK/
PI3K versus FAK/Src association in di¡erent cellular process-
es [9,11,18]. Binding of Src to FAK at Y397 allows Src to
phosphorylate Y925 of FAK, thus creating a binding site for
the adapter protein Grb2 [19,20]. Grb2 exists in complex with
SOS, and potentially links FAK to the Ras/MAPK cascade
[19]. FAK also contains proline-rich motifs capable of binding
the SH3 domain of the adapter protein p130Cas (Cas) [21]. Cas
is phosphorylated on multiple tyrosine residues by Src [22,23],
which forms binding sites for other signaling molecules bear-
ing SH2 domains [24].
Several previous studies have suggested a role for FAK
signaling pathways in the regulation of cell cycle progression
[4,6,10,25]. Microinjection of a FAK-inhibitory antibody
blocks the cell cycle at the G1/S boundary [25]. In addition,
microinjection of the C-terminal domain of FAK (i.e. FRNK)
causes cell cycle arrest [4]. One study has described a depen-
dence on FAK signaling to JNK through Cas for cell cycle
regulation [10]. Finally, our laboratory has shown that a trun-
cated FAK mutant (vC14) unable to localize to focal contacts
inhibits Erk activation and cell cycle progression through the
G1 phase [6] ; this e¡ect was dependent on the phosphoryla-
tion of Y397 [6]. While these studies clearly demonstrated a
role for FAK in the regulation of cell cycle progression, the
relative contributions made by distinct FAK signaling com-
plexes (e.g. FAK/PI3K versus FAK/Src) were not examined,
and to date poorly understood.
Here we investigate the role of several signaling molecules
that bind to FAK at phosphorylated Y397 including PI3K,
Src and Grb7. We showed that while FAK/PI3K and FAK/
Grb7 complexes are not involved, the FAK/Src complex plays
an essential role in the cell cycle regulation by FAK. Further-
more, we showed that FAK interactions with Grb2 and Cas,
both downstream events of FAK/Src complex formation, are
required for the regulation of cell cycle progression by FAK.
2. Materials and methods
2.1. Antibodies
The monoclonal antibody 12CA5 (K-HA) [26] and KT3 [5] have
been described previously. The rabbit polyclonal K-p85 [26] and K-KC
(K-FAK) [13] sera have also been described. The following antibodies
were purchased as indicated: K-BrdU mouse mAb from Sigma (St.
Louis, MO, USA); rabbit K-pErk from New England Biolabs (Bev-
erly, MA, USA), rabbit K-Src, and K-Erk from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA).
2.2. Constructs
The constructs pKH3-FAK, pKH3-FAK Y397F [26], pKH3-FAK
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D395A, pKH3-FAK P712/715A [9], pKH3-FAK vC14 [6], pDHGST
and pDHGST-Grb7 [17] have been described. The constructs
pCDM8-FAK, pCDM8-FAK Y397F [8] and pCDM8-FAK D395A
[9] have also been previously described. pKH3-FAK vC14F was gen-
erated by digesting pKH3-FAK Y397F with MscI and NheI. This 1.8
kb fragment was gel puri¢ed and subcloned into pKH3-FAK vC14 in
which the corresponding 1.8 kb fragment had been excized. Similarly,
pKH3-FAK vC14A was generated by digesting pKH3-FAK D395A
with MscI and NheI and subcloning this fragment into pKH3-FAK
vC14 as described above. pKH3-FAK Y925F and pKH3-FAK
COMBO were generated by digesting pCDM8-FAK Y925F and
pCDM8-FAK COMBO [8] with MscI and NheI and subcloning the
resulting fragments into pKH3-FAK, in which the corresponding
fragment had been removed.
2.3. Transient transfections
NIH 3T3 and HEK 293T cells were transfected with the indicated
constructs using the LipofectAmine and PLUS1 transfection reagents
(Life Technologies) according to the manufacturer’s instructions. NIH
3T3 cells were maintained in DME supplemented with 10% CS. These
were transfected with pKH3 (C), pKH3-FAK vC14, pKH3-FAK
vC14F, pKH3-FAK vC14A, pKH3-FAK Y925F, pKH3-FAK
P712/715A and pKH3-FAK COMBO. One day following transfec-
tion, cells were processed for the analysis of BrdU incorporation as
described below. HEK 293T cells were maintained in DME supple-
mented with 10% FBS. Cells were co-transfected with pDHGST-Grb7
and pCDM8-FAK, pCDM8-FAK Y397F, and pCDM8-FAK
D395A, or pDHGST and pCDM8-FAK. These were then processed
for pull-down assays 2 days following transfection.
2.4. Cell lines
pKH3-FAK D395A was digested with MscI and NheI. This 1.8 kb
fragment was subcloned into pTet-Splice FAK vC14 [6] in which the
corresponding fragment had been excized. Ligation of these fragments
produced pTet-Splice-FAK vC14A, and was co-transfected with
pTet-tTak and pSV2neo as described previously [6]. Likewise,
pKH3-FAK Y925F, pKH3-FAK P712/715A and pKH3-FAK COM-
BO were digested with MscI and NheI. These 1.8 kb fragments were
subcloned into pTet-Splice FAK [6] in which the corresponding frag-
ment had been excized. Ligation of these fragments produced pTet-
Splice-FAK Y925F, pTet-Splice-FAK P712/715A and pTet-Splice-
FAK COMBO. These were co-transfected with pTet-tTak and
pSV2neo as described previously [6]. For all, cells were selected in
medium containing 0.5 mg/ml G418 and screened for the inducible
expression of FAK vC14A and FAK Y925F, FAK P712/715A and
FAK COMBO as stated previously [6]. Cell lines capable of the in-
ducible expression of FAK vC14, FAK vC14F and control cells
(MOCK) have been described previously [6]. NIH 3T3 cells capable
of the inducible expression of the Grb7 SH2 domain have also been
described previously [17]. All cell lines were maintained in DME sup-
plemented with 10% CS, 0.5 mg/ml G418 and 0.4 Wg/ml tetracycline to
suppress the expression of the FAK constructs until required for the
indicated experiments. Induction of exogenous proteins was achieved
by culturing cell lines in DME supplemented with 10% CS and
0.5 mg/ml G418 for at least 16 h.
2.5. Cell lysis, immunoprecipitations and immunoblotting
Cells were washed twice with ice-cold phosphate-bu¡ered saline and
lyzed with RIPA bu¡er (50 mM HEPES, pH 7.4, 150 mM NaCl, 10%
glycerol, 1.5 mM MgCl2, 1 mM EGTA, 1 mM sodium vanadate, 10
mM sodium pyrophosphate, 10 mM NaF, 1% Triton X-100, 1% so-
dium deoxycholate, 0.1% sodium dodecylsulfate, 10 Wg/ml leupeptin
and 1 mM PMSF).
Lysates were cleared by centrifugation and total protein concentra-
tions were determined using the BioRad Protein assay (Hercules, CA,
USA). Immunoprecipitations were carried out at 4‡C by incubating
cell lysates with K-Src or K-p85 followed immediately by incubation
with protein G agarose (Sigma). After washing, the beads were resus-
pended in SDS^PAGE sample bu¡er, boiled and resolved via SDS^
PAGE.
Immunoblots were performed as indicated with K-HA (1:1000),
K-pErk (1:1000), K-Erk (1:1000), K-FAK (1:5000) and the KT3
mAb (1:5000) using the enhanced chemiluminescence system as de-
scribed [13]. In most experiments, equal amounts of WCL were ana-
lyzed directly by immunoblotting.
2.6. Pull-down assay
The association of Grb7 with FAK and its mutants was performed
as described previously [17]. Brie£y, transiently transfected HEK 293T
cells were starved in serum-free DME for 12 h, and re-plated on FN-
coated (10 Wg/ml) dishes in serum-free medium for 30 min and lyzed
in RIPA bu¡er. Lysates were incubated with glutathione agarose,
washed and resuspended in sample bu¡er and prepared for immuno-
blotting with the indicated antibodies.
2.7. Analysis of 5P-BrdU incorporation
Transiently transfected NIH 3T3 cells were serum starved for 48 h
in DME supplemented with 0.5% CS. They were then re-plated on
FN-coated (10 Wg/ml) glass coverslips and incubated for 16 h in the
presence of 100 WM BrdU in DME plus 10% CS. Cells were then
processed for immuno£uorescence staining with K-BrdU and
K-FAK as described [27]. The primary antibodies used were K-FAK
(1:300) and K-BrdU (1:300). The secondary antibodies used were
rhodamine-conjugated anti-mouse (1:300; Sigma) and FITC-conju-
gated anti-rabbit (1:300; Sigma). Cellular DNA was digested with
0.5 U/Wl DNaseI (New England Biolabs, Beverly, MA, USA) for
30 min at 37‡C prior to staining with the primary antibodies. At least
30 positively transiently transfected cells were scored for BrdU incor-
poration in each independent experiment. For experiments examining
DNA synthesis using the Grb7 SH2 inducible cell line, cells were
processed as described previously [6]. In all of the experiments listed
above, statistical analyses were performed using Minitab Xtra 10.5
software (Minitab, State College, PA, USA).
3. Results
Previous studies from our laboratory have suggested that
Y397 of FAK played an essential role in the regulation of cell
cycle progression by FAK [6]. PI3K association with receptor
tyrosine kinases has been shown to mediate mitogenic e¡ects
of growth factor signaling pathways [28]. Therefore, FAK
association with PI3K through Y397 might also play a role
in the downstream pathways leading to cell cycle regulation.
To investigate a potential role for the FAK/PI3K association,
we ¢rst tested whether a mislocalized FAK mutant (vC14),
which inhibited cell cycle progression [6], could bind to PI3K
as wild type FAK [26]. Lysates were prepared from NIH 3T3
cells inducibly overexpressing vC14 or vC14F (vC14 muta-
tion with Y397F), as well as control cells (Mock). Lysates
were then immunoprecipitated with K-p85 or K-Src followed
by immunoblotting with K-HA to detect the presence of HA-
tagged FAK mutants. Fig. 1 shows that vC14 was associated
with PI3K as well as Src in these cells. Mutation of Y397 to F
Fig. 1. FAK vC14 associates with PI3K. Lysates from NIH 3T3
cells induced to express vC14, vC14F or control cells (MOCK)
were immunoprecipitated with K-Src or K-p85 (regulatory subunit of
PI3K). The immunoprecipitates were analyzed by immunoblotting
with K-HA (middle and bottom panels). Aliquots of lysates were
also analyzed by immunoblotting with K-HA directly (top panel).
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abolished its binding to both PI3K and Src. Analysis of the
lysates by immunoblotting with K-HA directly con¢rmed sim-
ilar expression levels of vC14 and vC14F in these cells. To-
gether, these results suggested that vC14 might inhibit cell
cycle progression by competing with the endogenous FAK
for binding PI3K and/or Src family kinases.
To determine directly the potential role of a FAK/PI3K
complex in the regulation of cell cycle progression by integ-
rins, we created a FAK mutant with D395 mutated to A and
lacking the last 14 amino acids (vC14A). Mutation of D395 to
A selectively disrupts the association of FAK with PI3K, but
did not a¡ect FAK binding to Src [9]. Therefore, the mislo-
calized vC14A mutant is expected to inhibit the endogenous
FAK/Src complex, but not the FAK/PI3K complex. NIH 3T3
cells were transiently transfected with pKH3-FAK vC14A
(vC14A), pKH3-FAK vC14F (vC14F; Y397 mutated to F
and lacking the last 14 amino acids), or pKH3-FAK vC14
(vC14). Their e¡ects on cell cycle progression were evaluated
by measuring BrdU incorporation, as described previously [6].
Consistent with our previous results [6], Fig. 2A shows that
overexpression of vC14 inhibited cell cycle progression by
approximately 70% whereas the FAK mutant vC14F did
not signi¢cantly inhibit cell cycle progression. Interestingly,
the vC14A mutant inhibited cell cycle progression as e¡ec-
tively as the vC14 mutant. Comparable inhibition of cell cycle
progression by the vC14A mutant and the vC14 mutant was
also observed using NIH 3T3 cell lines with inducible expres-
sion of the mutants (data not shown). These results indicated
that the FAK/PI3K complex did not play a major role in the
cell cycle regulation and that disruption of the FAK com-
plexes with Src and potentially other signaling molecules (by
the vC14A mutant) was su⁄cient to block cell cycle progres-
sion.
Our previous studies suggested that the inhibition of cell
cycle progression by vC14 was mediated by its inhibition of
adhesion-induced Erk activation due to its disruption of en-
dogenous FAK signaling complexes [6]. To examine whether
vC14A inhibited cell cycle progression through the same
mechanism, we tested the e¡ect of vC14A on endogenous
Erk1/2 in the inducible NIH 3T3 cells. Lysates were prepared
from cells under induced conditions that had been replated on
¢bronectin. They were then analyzed for adhesion-induced
Erk activity using anti-phospho-Erk antibodies, as shown in
Fig. 2B. Consistent with previous observations [6], overexpres-
sion of vC14 inhibited Erk activation compared to Mock
cells. Consistent with its lack of inhibition of cell cycle pro-
gression, expression of vC14F did not reduce Erk activation
presumably due to its lack of e¡ects on either FAK/PI3K or
FAK/Src complexes. Interestingly, expression of vC14A also
inhibited Erk activation to a similar extent as vC14. Compa-
rable expression levels of various FAK mutants were con-
¢rmed by immunoblotting of the lysates with anti-HA (lower
panel). These results suggested that vC14A functioned to in-
hibit cell cycle progression in a manner similar to the vC14
mutant. They also suggested that disruption of the endoge-
nous FAK complexes with Src and potentially other signaling
molecules (by vC14A) could be su⁄cient to inhibit Erk acti-
vation in response to cell adhesion.
Recent studies suggested that Y397 of FAK also served as a
binding site for Grb7 [17]. To assess whether the FAK/Grb7
complex contributes to regulation of cell cycle progression, we
examined association of the D395A FAK mutant with Grb7.
293T cells were transiently co-transfected with pDHGST-
Grb7 encoding Grb7 fused to GST at the N-terminus
(GST^Grb7) and pCDM8-FAK (WT), pCDM8-FAK
Y397F (Y397F) or pCDM8-FAK D395A (D395A). Two
days after transfection, cells were lyzed and GST^Grb7 com-
plexes were precipitated with glutathione-coupled agarose
beads. After washing, the bound proteins were separated us-
ing SDS^PAGE and blotted with mAb KT3 to detect the
epitope-tagged FAK or its mutants (Fig. 3A, upper panel).
Consistent with the previous results [17], FAK, but not the
Y397F mutant, associated with Grb7 in transfected 293 cells.
Interestingly, the D395A mutant did not associate with Grb7.
The speci¢city of the association was veri¢ed by the lack of
co-precipitation of FAK when it was co-transfected with the
pDHGST vector (GST) alone. Similar expression levels for
FAK and mutants were con¢rmed by blotting whole cell ly-
sates with anti-FAK (Fig. 3A, lower panel). These results
indicated that the D395A mutation disrupted FAK associa-
tion with Grb7. Therefore, the vC14A mutant is not expected
to compete with endogenous FAK for Grb7 binding (thus will
not disrupt the endogenous FAK/Grb7 complex). The inhibi-
Fig. 2. PI3K association with FAK is not needed for FAK-regula-
tion of the cell cycle or Erk1/2 activity. A: NIH 3T3 cells were
transiently transfected with the indicated constructs and analyzed
for DNA synthesis, as described in Section 2. Results show the
mean+S.E.M. for at least three independent experiments. B: Lysates
were prepared from NIH 3T3 cells overexpressing FAK and its mu-
tants, as indicated. They were analyzed by immunoblotting with K-
pErk (top panel), K-Erk (middle panel) or K-HA (bottom panel).
Results are representative of two independent experiments.
FEBS 24388 11-12-00
H.R. Reiske et al./FEBS Letters 486 (2000) 275^280 277
tion of Erk activation and cell cycle progression by vC14A
(see Fig. 2) suggested that the FAK/Grb7 complex (even to-
gether with the FAK/PI3K complex) is not su⁄cient for these
events, and further highlights the importance of the FAK/Src
complex.
We have previously established a NIH 3T3 cell line with
inducible expression of the Grb7 SH2 domain alone [17]. In-
duction of the Grb7 SH2 domain resulted in a decrease in cell
migration on FN, suggesting that it can function in a domi-
nant negative manner to inhibit the endogenous FAK/Grb7
complex, which is involved in cell migration. In contrast, we
did not observe any di¡erences in BrdU incorporation of the
cell line under induced or uninduced conditions (Fig. 3B).
This provides further support for the above notion that the
FAK/Grb7 complex is not involved in the regulation of cell
cycle progression.
The formation of FAK/Src complex allows Src phosphory-
lation of FAK-bound Cas [22,23] and Y925 of FAK leading
to its association with Grb2 [19,20]. To further evaluate the
mechanisms of cell cycle regulation by the FAK/Src complex,
we investigated the role of FAK association with Cas and
Grb2 in the cell cycle regulation. Oktay et al. [10] have shown
previously that inhibition of Cas/Crk complex could block
FAK-dependent cell cycle progression. Although they sug-
gested that Cas phosphorylation and its complex with Crk
is required for FAK regulation of cell cycle progression, these
results did not address the potential importance of direct as-
sociation of FAK with Cas. The potential role of FAK/Grb2
association in cell cycle progression is unknown, although this
complex has been suggested to play a role in Erk activation by
FAK [19]. NIH 3T3 cells were transiently transfected with
pKH3-FAK Y925F (Y925F) or pKH3-FAK P712/715A
(P712/715A), which do not associate with Grb2 or Cas, re-
spectively, and the e¡ects of these mutants on cell cycle pro-
gression were evaluated by measuring BrdU incorporation, as
described previously [6]. Fig. 4 shows that overexpression of
either P712/715A or Y925F mutants inhibited cell cycle pro-
gression by approximately 50% when compared with the
Mock transfected cells. Transfection of pKH3-FAK COMBO
(COMBO; P712 and P715 mutated to A and Y925 mutated to
F) resulted in a more signi¢cant inhibition than either of the
single mutants. Similar results were obtained in stable NIH
3T3 cell lines with inducible expression of the FAK P712/
715A, Y925F or the combo mutant (data not shown). Togeth-
er, these results suggested that FAK association with both
Cas and Grb2 are involved in the regulation of cell cycle
progression and the two complexes might work in parallel
pathways.
4. Discussion
Integrin signaling through FAK has been shown to regulate
a variety of cellular processes including cell spreading and
migration, cell survival and apoptosis, and cell cycle progres-
sion [1,2]. It has been suggested that FAK regulated these
cellular functions through its interaction with a variety of
other signaling molecules. However, the speci¢c contributions
of distinct FAK signaling complexes toward FAK-regulation
of these cellular processes are poorly understood. Using spe-
ci¢c FAK mutants de¢cient in binding to speci¢c partners, we
showed that FAK association with PI3K or Grb7 is not in-
volved in the regulation of cell cycle progression by FAK,
while the FAK/Src complex plays an important role in this
process. Furthermore, we found that FAK interactions with
Fig. 3. FAK association with Grb7 is not required for cell cycle
progression. A: HEK 293T cells were co-transfected with GST^
Grb7 or GST and FAK or its mutants as indicated. Lysates were
then prepared from these cells, incubated with glutathione agarose
(Pull-down) and analyzed by immunoblotting with KT3 (top panel).
Aliquots of lysates were also analyzed by immunoblotting with
K-FAK directly (lower panel). B: The Grb7 SH2 inducible cell line
was cultured in the presence (U) or absence (I) of tetracycline to re-
press or induce the expression of Grb7 SH2. These were analyzed
for DNA synthesis, as described in Section 2. Results show the
mean+S.E.M. for at least two independent experiments.
Fig. 4. Grb2 and Cas association with FAK are required for cellular
proliferation. NIH 3T3 cells were transiently transfected with the in-
dicated constructs and analyzed for DNA synthesis, as described in
Section 2. Results show the mean+S.E.M. for at least three inde-
pendent experiments.
FEBS 24388 11-12-00
H.R. Reiske et al./FEBS Letters 486 (2000) 275^280278
Cas or Grb2 are both required for the regulation of cellular
proliferation.
Previous studies from our laboratory have shown that a
mislocalized FAK mutant, vC14, inhibited cell cycle progres-
sion. This inhibition was dependent on Y397 of FAK [6].
Since Y397 is a binding site for a number of signaling mole-
cules including Src [13,14], PI3K [15], Grb7 [17] and PLCQ1
[16], these studies implicated a role for FAK complexes with
these molecules although the contribution by each signaling
complex (e.g. FAK/Src versus FAK/PI3K) was not deter-
mined. We have recently generated a mutation (D395A) in
FAK that selectively disrupts the association of FAK with
PI3K, while leaving all Src-dependent elements of FAK func-
tion unchanged [9]. Additional analysis here indicates that the
D395A mutation also disrupts FAK/Grb7 association (Fig.
3). Use of this mutation in the context of the vC14 back-
ground (i.e. vC14A) allowed us to assess the roles of the
FAK/Src complex versus FAK association with PI3K and
Grb7. We found that vC14A was able to inhibit cell cycle
progression as e¡ectively as the vC14 mutant (Fig. 2), even
though it could not compete with the endogenous FAK for
binding PI3K and Grb7. If either the FAK/PI3K or the FAK/
Grb7 complexes were playing a role in cell cycle progression,
free PI3K and/or Grb7 would be expected to relieve, at least
partially, the inhibition of cell cycle progression by vC14. In
addition, a dominant negative Grb7 mutant [17] failed to
a¡ect DNA synthesis (Fig. 3B). Together these results sug-
gested that FAK/PI3K and FAK/Grb7 were not involved in
FAK-regulated cell cycle progression. They provided the ¢rst
example that particular FAK signaling complexes (e.g. FAK/
PI3K) are involved in a subset ([17], this study), but not all, of
FAK-regulated cellular functions.
Results presented here suggested that the FAK/Src complex
might regulate cell cycle progression through multiple down-
stream pathways. We found that FAK interaction with Cas
and Grb2, both downstream events of FAK/Src complex for-
mation [19,20,22,23], were necessary for the regulation of cell
cycle progression by FAK. Expression of either FAK mutant
lacking binding to Cas or Grb2 each inhibited cell cycle pro-
gression (Fig. 4). A previous report has suggested that FAK
signaled through Cas to JNK in the regulation of cell cycle
progression [10]. However, these experiments did not investi-
gate FAK/Cas association directly. Reagents that block total
JNK or Cas function may be interfering with cell cycling
pathways that do not involve FAK. Furthermore, Cas-bound
Crk can associate with the GEF C3G [22] that can potentially
activate the Ras/Erk cascade, thus a role for Cas in signaling
to Erk cannot be discounted. Nonetheless, FAK/Src signaling
through Cas could potentially regulate cell cycling indepen-
dently of Erk, signaling through JNK. Indeed, preliminary
data from our laboratory suggests that FAK/Cas association
is required for adhesion-stimulated JNK2 activation (data not
shown).
The mechanism by which the FAK Y925F mutant lacking
Grb2 binding inhibited cell cycle progression is not clear at
present. Previous studies suggested that FAK association with
Grb2 at Y925 contributes to Erk activation in cell adhesion
[29] or upon HGF-stimulation [30]. Thus, it is possible that
Grb2 binding to Y925 of FAK plays a role in regulating cell
cycle progression through its e¡ects on Erk activation. Alter-
natively, Grb2 binding to FAK at Y925 may couple FAK to
other cellular proteins such as dynamin [31], which may con-
tribute to cell cycle regulation in an Erk-independent manner.
Dynamin is involved in the regulation of endocytosis and
receptor internalization [32], and Grb2 association with dyna-
min has been shown to mediate signaling in response to
growth factors distinct from that of the Grb2/SOS complex
[33]. Finally, we cannot exclude the possibility that FAK may
interact with other proteins through Y925, which may con-
tribute to FAK/Src-dependent regulation of cell cycle progres-
sion. Further studies will be necessary to clarify the various
possibilities.
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